HealthEquity, Inc. (NASDAQ:HQY) Receives Consensus Recommendation of “Buy” from Analysts

Shares of HealthEquity, Inc. (NASDAQ:HQY) have been given a consensus recommendation of “Buy” by the twelve ratings firms that are currently covering the company, Marketbeat Ratings reports. Twelve analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in the last year is $103.83.

Several equities research analysts have recently commented on HQY shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Wells Fargo & Company upped their target price on HealthEquity from $107.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, June 20th. KeyCorp upped their target price on HealthEquity from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. Deutsche Bank Aktiengesellschaft upped their target price on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Bank of America reduced their price objective on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th.

HealthEquity Trading Down 1.9 %

Shares of HQY stock opened at $80.27 on Friday. The stock has a 50-day simple moving average of $76.42 and a 200 day simple moving average of $79.21. HealthEquity has a fifty-two week low of $61.81 and a fifty-two week high of $88.26. The stock has a market capitalization of $6.98 billion, a P/E ratio of 87.25, a P/E/G ratio of 1.25 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last announced its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The business had revenue of $299.93 million during the quarter, compared to analysts’ expectations of $284.48 million. On average, sell-side analysts expect that HealthEquity will post 2.25 earnings per share for the current fiscal year.

Insider Transactions at HealthEquity

In other news, Vice Chairman Stephen Neeleman sold 35,000 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the sale, the insider now directly owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Frank Corvino sold 7,705 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $81.89, for a total transaction of $630,962.45. Following the completion of the sale, the director now directly owns 6,070 shares of the company’s stock, valued at approximately $497,072.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the transaction, the insider now directly owns 89,769 shares in the company, valued at approximately $7,168,952.34. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Rise Advisors LLC acquired a new position in shares of HealthEquity during the 1st quarter valued at about $28,000. International Assets Investment Management LLC acquired a new stake in HealthEquity in the 2nd quarter valued at approximately $35,000. YHB Investment Advisors Inc. acquired a new stake in HealthEquity in the 1st quarter valued at approximately $40,000. Fidelis Capital Partners LLC acquired a new stake in HealthEquity in the 1st quarter valued at approximately $42,000. Finally, Parallel Advisors LLC grew its holdings in HealthEquity by 255.5% in the 4th quarter. Parallel Advisors LLC now owns 679 shares of the company’s stock valued at $45,000 after buying an additional 488 shares during the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.